FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Wofsy

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Physiology

Lymphocyte Activation

Procedures

Lymphocyte Depletion

Co-author Network

Publications

TOP 3
David Wofsy
Recent progress in conventional and biologic therapy for systemic lupus erythematosus.
David Wofsy; Jan L Hillson; Betty Diamond
Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.
Mary Anne Dooley; Frank Eitner; Ellen M Ginzler; David Isenberg; David Jayne; Laura Lisk; Nancy J Olsen; Neil Solomons; David Wofsy; Gerald B Appel; Gabriel Contreras
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Wofsy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: David Wofsy
Recent progress in conventional and biologic therapy for systemic lupus erythematosus.
Annals of the rheumatic diseases 2013;72 Suppl 2():ii66-8.
2012: David Wofsy; Jan L Hillson; Betty Diamond
Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.
Arthritis and rheumatism 2012;64(11):3660-5.
2011: Mary Anne Dooley; Frank Eitner; Ellen M Ginzler; David Isenberg; David Jayne; Laura Lisk; Nancy J Olsen; Neil Solomons; David Wofsy; Gerald B Appel; Gabriel Contreras
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
The New England journal of medicine 2011;365(20):1886-95.
2011: Maria Dall'Era; Victoria Levesque; David Stone; Miriam Cisternas; David Wofsy
Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
Arthritis care & research 2011;63(3):351-7.
2010: Maxine A Papadakis; David Wofsy
Plagiarism on personal statements: a disturbing symptom of a broader trend.
Annals of internal medicine 2010;153(2):128-9.
2010: Maria Dall'Era; David Wofsy
Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through?
Nature reviews. Rheumatology 2010;6(3):124-5.
2010: Maria Dall'Era; David Wofsy
Biologic therapy for systemic lupus erythematosus.
Discovery medicine 2010;9(44):20-3.
2010: David Isenberg; Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Jayne; Jorge Sánchez-Guerrero; David Wofsy; Xueqing Yu; Neil Solomons
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.
Rheumatology (Oxford, England) 2010;49(1):128-40.
2009: Jonathan Esensten; David Wofsy; Jeffrey A Bluestone
Regulatory T cells as therapeutic targets in rheumatoid arthritis.
Nature reviews. Rheumatology 2009;5(10):560-5.
2009: Maria Dall'Era; David Wofsy
Systemic lupus erythematosus clinical trials-an interim analysis.
Nature reviews. Rheumatology 2009;5(6):348-51.
2009: Jinoos Yazdany; Pantelis Panopalis; Joann Zell Gillis; Gabriela Schmajuk; Catherine H MacLean; David Wofsy; Edward H Yelin
A quality indicator set for systemic lupus erythematosus.
Arthritis and rheumatism 2009;61(3):370-7.
2006: Maria Dall'Era; David Wofsy
Clinical trial design in systemic lupus erythematosus.
Current opinion in rheumatology 2006;18(5):476-80.
2006: David I Daikh; Joann Gillis; David Wofsy
Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases.
Arthritis and rheumatism 2006;55(2):322-4.
2005: David Wofsy
Living in a different world.
Arthritis and rheumatism 2005;52(2):395-401.
2002: Kenneth C Kalunian; John C Davis; Joan T Merrill; Mark C Totoritis; David Wofsy
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
Arthritis and rheumatism 2002;46(12):3251-8.
2001: David I Daikh; David Wofsy
Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(5):2913-6.
2001: T Wada; Andreas Schwarting; Mark S Chesnutt; David Wofsy; V Rubin Kelley
Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets.
Kidney international 2001;59(2):565-78.
2001: David I Daikh; David Wofsy
Treatment of autoimmunity by inhibition of T cell costimulation.
Advances in experimental medicine and biology 2001;490():113-7.
2001: John C Davis; Mark C Totoritis; J Rosenberg; T A Sklenar; David Wofsy
Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
The Journal of rheumatology 2001;28(1):95-101.
1999: P Jeddi; J Keusch; Peter M Lydyard; K B Bodman-Smith; Mark S Chesnutt; David Wofsy; H Hirota; T Taga; Peter J Delves
The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G.
Immunology 1999;98(3):475-80.
1999: David I Daikh; David Wofsy
Effects of anti-B7 monoclonal antibodies on humoral immune responses.
Journal of autoimmunity 1999;12(2):101-8.
1998: David I Daikh; David Wofsy
On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases.
Transplantation proceedings 1998;30(8):4027-8.
1998: David Wofsy; David I Daikh
Opportunities for future biological therapy in SLE.
Baillière's clinical rheumatology 1998;12(3):529-41.
1998: Mark S Chesnutt; barbara finck; N Killeen; M K Connolly; H Goodman; David Wofsy
Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice.
Clinical immunology and immunopathology 1998;87(1):23-32.
1997: David I Daikh; barbara finck; Peter Linsley; Diane L Hollenbaugh; David Wofsy
Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(7):3104-8.
1996: Leonard Adleman; David Wofsy
Blind T-cell homeostasis in CD4-deficient mice.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(4):334-40.
1994: barbara finck; Peter Linsley; David Wofsy
Treatment of murine lupus with CTLA4Ig.
Science (New York, N.Y.) 1994;265(5176):1225-7.
1994: M K Connolly; E A Kitchens; B Chan; P Jardieu; David Wofsy
Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy.
Clinical immunology and immunopathology 1994;72(2):198-203.
1994: barbara finck; B Chan; David Wofsy
Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.
The Journal of clinical investigation 1994;94(2):585-91.
1993: Leonard Adleman; David Wofsy
T-cell homeostasis: implications in HIV infection .
Journal of acquired immune deficiency syndromes 1993;6(2):144-52.
1992: barbara finck; C M Yung; N L Carteron; David Wofsy
The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies.
Clinical immunology and immunopathology 1992;65(3):234-41.
1992: K Connolly; J R Roubinian; David Wofsy
Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(9):3083-8.
1990: David Wofsy; N L Carteron
CD4 antibody therapy in systemic lupus erythematosus.
Seminars in immunology 1990;2(6):419-25.
1990: David Wofsy
Regulation of immunity by anti-T-cell antibodies.
The Western journal of medicine 1990;153(3):265-8.
1990: N L Carteron; David Wofsy; C Schimenti; Thomas H Ermak
F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T cells, CD8+ T cells, and B cells in the kidneys of lupus-prone NZB/NZW mice.
Clinical immunology and immunopathology 1990;56(3):373-83.
1990: C Gordon; David Wofsy
Effects of recombinant murine tumor necrosis factor-alpha on immune function.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(5):1753-8.
1989: Thomas H Ermak; H J Steger; David Wofsy
Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node.
Laboratory investigation; a journal of technical methods and pathology 1989;61(4):447-56.
1989: C Gordon; G E Ranges; John Greenspan; David Wofsy
Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.
Clinical immunology and immunopathology 1989;52(3):421-34.
1989: K S Erlich; David Wofsy; Richard Dix; John Mills
Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis.
Clinical immunology and immunopathology 1989;52(2):190-201.
1989: N L Carteron; C L Schimenti; David Wofsy
Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(5):1470-5.
1988: David Wofsy; N Y Chiang; John Greenspan; Thomas H Ermak
Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune disease.
Journal of autoimmunity 1988;1(5):415-31.
1988: David Wofsy
The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus.
Journal of autoimmunity 1988;1(2):207-17.
1988: N L Carteron; David Wofsy; William Seaman
Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(3):713-6.
1988: William Seaman; David Wofsy
Selective manipulation of the immune response in vivo by monoclonal antibodies.
Annual review of medicine 1988;39():231-41.
1987: David Wofsy; N Y Chiang
Proliferation of Ly-1 B cells in autoimmune NZB and (NZB x NZW)F1 mice.
European journal of immunology 1987;17(6):809-14.
1987: David Wofsy; William Seaman
Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(10):3247-53.
1986: N L Gutstein; David Wofsy
Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(11):3414-9.
1986: J Woodcock; David Wofsy; E Eriksson; J H Scott; William Seaman
Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells.
Transplantation 1986;42(6):636-42.
1986: N L Gutstein; William Seaman; J H Scott; David Wofsy
Induction of immune tolerance by administration of monoclonal antibody to L3T4.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(4):1127-32.
1986: David Wofsy; William Seaman
Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4.
Immunologic research 1986;5(2):97-105.
1985: David Wofsy; D C Mayes; J Woodcock; William Seaman
Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(3):1698-701.
1985: David Wofsy; William Seaman
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.
The Journal of experimental medicine 1985;161(2):378-91.
1985: David Wofsy; J A Ledbetter; P L Hendler; William Seaman
Treatment of murine lupus with monoclonal anti-T cell antibody.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(2):852-7.
1984: David Wofsy; R R Hardy; William Seaman
The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T cells that is involved in the response to class II major histocompatibility antigens.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(6):2686-9.
1984: David Wofsy; C E Kerger; William Seaman
Monocytosis in the BXSB model for systemic lupus erythematosus.
The Journal of experimental medicine 1984;159(2):629-34.
1983: William Seaman; David Wofsy; John Greenspan; J A Ledbetter
Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.
Journal of immunology (Baltimore, Md. : 1950) 1983;130(4):1713-8.
1982: David Wofsy; J A Ledbetter; J R Roubinian; William Seaman; N Talal
Thymic influences on autoimmunity in MRL-lpr mice.
Scandinavian journal of immunology 1982;16(1):51-8.